3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
4
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Myeloid
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
302
Parkinson Disease 4, Autosomal Dominant Lewy Body
180
Melanoma
166
Neoplasms
133
Squamous Cell Carcinoma of Head and Neck
126
Neoplasm Metastasis
98
Colorectal Neoplasms
96
Carcinoma, Renal Cell
80
Triple Negative Breast Neoplasms
75
Head and Neck Neoplasms
72
Stomach Neoplasms
70
Lung Neoplasms
68
Breast Neoplasms
60
Ovarian Neoplasms
56
Carcinoma, Transitional Cell
51
Uterine Cervical Neoplasms
44
Endometrial Neoplasms
44
Pancreatic Neoplasms
43
Urinary Bladder Neoplasms
40
Esophageal Neoplasms
40
Carcinoma, Hepatocellular
37
Small Cell Lung Carcinoma
30
Cholangiocarcinoma
24
Prostatic Neoplasms
22
Carcinoma
22
Lymphoma
20
Carcinoma, Squamous Cell
20
Recurrence
17
Sarcoma
16
Esophageal Squamous Cell Carcinoma
16
Interventions
Azacitidine
66
venetoclax
21
Decitabine
16
Cytarabine
12
decitabine and cedazuridine drug combination
10
AP 1903 reagent
10
Cyclophosphamide
7
fludarabine
6
pevonedistat
5
mocetinostat
5
ON 01910
5
Busulfan
5
treosulfan
4
sabatolimab
4
ruxolitinib
4
cedazuridine
4
cc-486
4
Mycophenolic Acid
4
Lenalidomide
4
Injections
4
plerixafor
3
luspatercept
3
imetelstat
3
glasdegib
3
fludarabine phosphate
3
Whole-Body Irradiation
3
Methotrexate
3
GRN163L peptide
3
Clofarabine
3
CPX-351
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Myelodysplastic Syndromes
×
pembrolizumab
×
Clear all
NCT01953692
2021-08-04
MK-3475-013
Merck Sharp & Dohme LLC
Phase 1
Completed
197 enrolled
52 charts